Who are Varubi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Akynzeo, Akynzeo, Emend, Emend, Zunrisa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rolapitant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Varubi — Competitive Intelligence Brief

Varubi (ROLAPITANT) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Substance P/Neurokinin-1 Receptor Antagonist. Area: Oncology.

marketed Substance P/Neurokinin-1 Receptor Antagonist Substance-P receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Varubi (ROLAPITANT) — Tersera. Varubi works by blocking the substance-P receptor, a key player in the body's response to chemotherapy-induced nausea and vomiting.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Varubi TARGET	ROLAPITANT	Tersera	marketed	Substance P/Neurokinin-1 Receptor Antagonist	Substance-P receptor	2015-01-01
Akynzeo	FOSNETUPITANT	Helsinn Hlthcare	marketed	Serotonin-3 Receptor Antagonist [EPC]	Substance-P receptor	2018-01-01
Akynzeo	NETUPITANT	Helsinn Hlthcare	marketed	Serotonin-3 Receptor Antagonist [EPC]	Substance-P receptor	2014-01-01
Emend	APREPITANT	Merck & Co.	marketed	Substance P/Neurokinin-1 Receptor Antagonist [EPC]	Substance-P receptor	2003-01-01
Emend	FOSAPREPITANT		marketed	Substance P/Neurokinin-1 Receptor Antagonist	Substance-P receptor	2003-01-01
Zunrisa	CASOPITANT		phase 3	casopitant	Sigma non-opioid intracellular receptor 1, Substance-P receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-11-18 — Akynzeo · 9186357 · US
2030-11-18 — Akynzeo · 9943515 · US
2030-11-18 — Akynzeo · 9186357 · US
2030-11-18 — Akynzeo · 8951969 · US
2030-11-18 — Akynzeo · 8623826 · US
2030-11-18 — Akynzeo · 11559523 · US
2030-12-17 — Akynzeo · 10828297 · US
2030-12-17 — Akynzeo · 10828297 · US
2031-09-09 — Akynzeo · 9271975 · US
2032-05-23 — Akynzeo · 10717721 · US
2032-05-23 — Akynzeo · 8895586 · US
2032-05-23 — Akynzeo · 9403772 · US
2032-05-23 — Akynzeo · 9908907 · US
2032-05-23 — Akynzeo · 10208073 · US
2032-05-23 — Akynzeo · 8426450 · US
2032-05-23 — Akynzeo · 11312698 · US
2035-09-25 — Akynzeo · 10676440 · US
2035-09-25 — Akynzeo · 10233154 · US
2035-09-25 — Akynzeo · 9951016 · US
2035-09-25 — Akynzeo · 10961195 · US
2037-06-02 — Akynzeo · 11529362 · US
2037-06-02 — Akynzeo · 10624911 · US

Sponsor landscape (Substance P/Neurokinin-1 Receptor Antagonist class)

· 1 drug in this class
Tersera · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Varubi — Competitive Intelligence Brief. https://druglandscape.com/ci/rolapitant. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab